AbbVie Sold AndroGel Without Heart Risk Warning, Jury Told
AbbVie Inc. knew its product AndroGel wasn't approved to treat age-related drops in testosterone, but the company marketed it for that while downplaying an associated risk of heart attacks, attorneys for...To view the full article, register now.
Already a subscriber? Click here to view full article